Sylvain Jereme M sold $303K of DXCM
Sylvain Jereme M (EVP, Chief Financal Officer) sold 3,638 shares of DEXCOM INC (DXCM) at $83.27 ($0.30M total) on 2026-09-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings, offering a modest trading signal.
Market read
A small insider sale by the CFO may cause slight short-term price pressure but is unlikely to drive major market moves.
What to watch
Potential upcoming earnings or corporate actions that could contextualize the sale.
Background
Form 4 filings disclose insider transactions; CFO sales are closely watched by investors.
Ticker impact
CFO Sylvain Jereme M sold 3,638 shares for $302,936 via a 10b5-1 plan, reducing his stake to 146,828 shares.
Possible modest downside pressure in the next few trading sessions.
The sale size is modest relative to market cap, but CFO involvement and use of a pre-arranged plan can influence sentiment.
Market effects
Minimal impact on the broader medical device sector.
U.S. market only; no regional ripple.
Low global relevance.
Counterpoint
The sale may be purely procedural under the 10b5-1 plan, not reflecting any negative outlook.
Key entities
- CompanyDexcom Inc.
Medical device maker specializing in continuous glucose monitoring.
- ExecutiveSylvain Jereme M
Executive Vice President and Chief Financial Officer of Dexcom.
